Quest Diagnostics' revenues fell in the fourth quarter of 2013--a direct violation of its 5-point strategy including "restore growth"--but the company thinks its acquisition of prevention and wellness services outfit Summit Health will help fix those problems.
A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi's cell therapy and regenerative medicine business for the low, low purchase price of $6.5 million--$4 million payable in cash and $2.5 million in a promissory note.
We thought Pfizer was on a diet. After all, CEO Ian Read has garnered investor acclaim for his unit sales and spinoffs, and more of that action is expected. But the U.S.-based drug behemoth reportedly made a $100 billion-plus merger pitch to its struggling rival AstraZeneca. That would be quite a deal to digest.
OPKO Health said it has reached an agreement to acquire Inspiro Medical, an Israel-based company that makes an inhaler for the treatment of respiratory diseases.
Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.
It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 billion.
All things being relative, 2013 was a pretty good year for M&A in pharma. There were 169 deals valued at $76 billion last year, according to the information ninjas who dice the numbers at...
Surgical device maker Conmed ($CNMD) is said to be putting itself up for sale, ostensibly to avoid trouble from activist shareholders at its annual meeting later this year.
European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.
Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.